Corvus Pharmaceuticals, Inc. (CRVS)
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$15.3M
- Total assets
- $71.1M
- Market cap
- $935.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $43.0M
- Operating income
- -$43.0M
- Income tax
- $0
- Net income
- -$15.3M
- EPS (basic)
- $-0.19
- EPS (diluted)
- $-0.53
Balance sheet
- Total assets
- $71.1M
- Current assets
- $58.2M
- Total liabilities
- $9.9M
- Current liabilities
- $9.4M
- Shareholders’ equity
- $61.2M
Cash flow
- Operating cash flow
- -$32.8M
- Investing cash flow
- -$7.8M
- Financing cash flow
- $36.4M
- Net cash flow
- -$4.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $935.1M
- EPS (diluted)
- $-0.53
- Shares outstanding
- 71.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 23, 2016
Corvus Pharmaceuticals, Inc. (CRVS) Stock Price
- Reported a net loss of $15.3M.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Corvus Pharmaceuticals, Inc..
Write a review
News about Corvus Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Corvus Pharmaceuticals, Inc.: frequently asked questions
Is Corvus Pharmaceuticals, Inc. an American company?
Corvus Pharmaceuticals, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Corvus Pharmaceuticals, Inc. headquartered?
Corvus Pharmaceuticals, Inc. is headquartered in South San Francisco, California, United States.
Is Corvus Pharmaceuticals, Inc. publicly traded?
Yes — Corvus Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol CRVS on the NASDAQ.
What does Corvus Pharmaceuticals, Inc. do?
Corvus Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
